Zentalis Pharmaceuticals, Inc. (ZNTL) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Zentalis Pharmaceuticals, Inc. (ZNTL) Earnings Overview
As of July 7, 2026, Zentalis Pharmaceuticals, Inc. (ZNTL) reported trailing twelve-month net income of -$124M, reflecting +18.0% year-over-year growth. The company earned $-1.77 per diluted share over the past four quarters.
Looking at the long-term picture, ZNTL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$21M in fiscal 2018.
Zentalis Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RVMD (-$1.37B net income), KYMR (-$315M net income, -794.4% margin), AUPH ($298M net income, 101.5% margin), ZNTL has comparable earnings metrics. Compare ZNTL vs RVMD →
ZNTL Earnings vs Peers
Earnings metrics vs comparable public companies
ZNTL Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$137M | +17.4% | -$153M | $-1.91 | - | - |
| 2024 | -$166M | +43.2% | -$191M | $-2.33 | -246.0% | -283.6% |
| 2023 | -$292M | -23.4% | -$300M | $-4.47 | - | - |
| 2022 | -$237M | -49.2% | -$227M | $-4.48 | - | - |
| 2021 | -$159M | -34.7% | -$217M | $-3.72 | - | - |
| 2020 | -$118M | -158.1% | -$119M | $-2.87 | - | - |
| 2019 | -$46M | -116.8% | -$47M | $-1.29 | - | - |
| 2018 | -$21M | - | -$24M | $-1.17 | -150478.6% | -169878.6% |
Download Data
Export ZNTL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZNTL — Frequently Asked Questions
Quick answers to the most common questions about buying ZNTL stock.
What is ZNTL earnings per share (EPS)?
ZNTL trailing twelve-month (TTM) diluted EPS is $-1.77, reflecting +18.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Zentalis Pharmaceuticals, Inc.'s net income?
Zentalis Pharmaceuticals, Inc. (ZNTL) trailing twelve-month net income is $-124M as of 2025. Earnings grew +18.0% year-over-year.
Is ZNTL profitable?
ZNTL is not currently profitable on a TTM basis, reporting a net loss of $-124M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ZNTL's earnings growth rate?
ZNTL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are ZNTL's profit margins?
Zentalis Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -49.5%.
Is ZNTL growing earnings?
Yes, ZNTL earnings are accelerating — EPS growth of +18.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-124M. Earnings momentum is strengthening.
What was ZNTL's best earnings year?
Zentalis Pharmaceuticals, Inc.'s highest annual net income on record is $-21M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were ZNTL's earnings last quarter?
ZNTL's most recent reported quarter was Q1 2026. Net income was $-35M with diluted EPS of $-0.50. For a full breakdown of all quarters, see the quarterly earnings table on this page.